

Amendment to the claims:

This listing of claims will replace all prior versions and listings of claims in the application:

1-5. (Cancelled).

6. (Currently amended) ~~A~~ An immunogenic compound for vaccination of an animal comprising (i) HIV gp120, or parts thereof, and (ii) an antigen, wherein the antigen is a molecule associated with a disease of the animal or part or variant of such a molecule, wherein the antigen elicits an immune response to the disease, wherein the HIV gp120 and the antigen each comprise a polypeptide and both are present in the same polypeptide chain.

7-8. (Cancelled).

9. (Previously presented) The compound according to Claim 6, wherein the antigen comprises two or more molecules associated with a disease of the animal or parts or variants of such molecules.

10. (Previously presented) The compound according to Claim 6, wherein the antigen is an antigenic component of a pathogen or a tumour or an antigenic part or variant of such a component.

11. (original) The compound according to Claim 10, wherein the pathogen is any of a bacterium, virus, fungus, protozoa or helminth.

12. (Currently amended) The compound according to Claim 6, wherein the antigen is an antigenic component of a pathogen ~~selected from pathogens~~ associated with ~~OIE list A diseases~~ a disease selected from the group consisting of: foot and mouth disease, swine vesicular disease, peste des petits ruminants, lumpy skin disease, bluetongue, African horse sickness, classical swine fever, Newcastle disease, vesicular stomatitis, rinderpest, contagious bovine pleuropneumonia, Rift Valley fever, sheep pox and goat pox, African swine fever, and highly pathogenic avian influenza, or a part or variant of such a component.

13-17. (Cancelled).

18. (Previously presented) A vaccine comprising the compound according to Claim 6.

19. (Previously presented) The vaccine according to Claim 18 further comprising an adjuvant.

20. (Cancelled).

21. (Previously presented) A pharmaceutical composition comprising a compound according to Claim 6 and a pharmaceutically acceptable carrier.

22. (Withdrawn-currently amended) A method of immunizing an animal against a disease, the method comprising the step of administering to the animal a compound according to Claim 6.

23. (Withdrawn) A method of combating a disease in an animal, the method comprising the step of administering to the animal a compound according to Claim 6.

24. (Withdrawn) The method according to any one of Claims 22 or 23 wherein the disease is one caused by a pathogen.

25. (Withdrawn) The method according to Claim 24 wherein the pathogen is any of a bacterium, virus, fungus, protozoa or helminth.

26. (Withdrawn-currently amended) The method according to Claim 25 wherein the pathogen is one associated with ~~OIE List A diseases~~ a disease selected from the group consisting of: foot and mouth disease, swine vesicular disease, peste des petits ruminants, lumpy skin disease, bluetongue, African horse sickness, classical swine fever, Newcastle disease, vesicular stomatitis, rinderpest, contagious bovine pleuropneumonia, Rift Valley fever, sheep pox and goat pox, African swine fever, and highly pathogenic avian influenza.

27. (Withdrawn) The method according to any one of Claim 22 or 23 wherein the animal is a mammal.

28. (Withdrawn) The method according to Claim 22 wherein the animal is a companion animal or farm animal.

29. (Withdrawn) The method according to Claim 28 wherein the animal is a cow, sheep, horse, pig, goat, dog, cat or rabbit.

30-37. (Cancelled).

38. (Currently amended) A method of making the compound of Claim 6, the method comprising co-expressing ~~linking~~ the HIV gp120, or a part thereof, with the said antigen.

39-44. (cancelled).

45. (Withdrawn) A method of determining whether an animal has been administered a the compound of Claim 6, the method comprising determining whether the animal has or had an immune response to HIV gp120.

46. (Withdrawn) The method of Claim 45 further comprising determining whether the animal has or had an immune response to the antigen.

47. (Withdrawn) A kit comprising

- (i) the compound of Claim 6 or Claim 52;
- (ii) part for detecting an immune response to HIV gp120; or
- (iii) part for detecting an immune response to the antigen.

48. (Withdrawn) The kit of Claim 47, wherein (ii) comprises all or a portion of HIV gp120 that binds to an antibody raised against said all or a portion of HIV gp120, wherein (iii)

comprises all, or a portion, of said antigen that binds to an antibody raised against said antigen.

49. (Cancelled).

50. (Withdrawn) The kit of Claim 47, wherein (ii) and (iii) each comprises an ELISA.

51. (Cancelled).

52. (New) An immunogenic compound for vaccination of an animal comprising (i) HIV gp120, or parts thereof, and (ii) an antigen, wherein the antigen is an antigenic component of a tumor or a pathogen of the animal, wherein the antigen elicits an immune response to the tumor or the pathogen, wherein said pathogen is selected from the group consisting of viruses, fungi, protozoa and helminths.

53. (New) The compound according to Claim 52, wherein the antigen is a polypeptide.

54. (New) The compound according to Claim 52, wherein the antigen comprises two or more molecules associated with a disease of the animal or parts or variants of such molecules.

55. (New) The compound according to Claim 52, wherein the antigen is an antigenic component of a pathogen associated with a disease selected from foot and mouth disease, swine vesicular disease, peste des petits ruminants, lumpy skin disease, bluetongue, African horse sickness, classical swine fever, Newcastle disease, vesicular stomatitis, rinderpest, Rift Valley fever, sheep pox and goat pox, African swine fever and highly pathogenic avian influenza, or a part or variant of such a component.

56. (New) The compound according to Claim 52, wherein the HIV gp120 and the antigen are covalently linked.

57. (New) A method of making the compound of Claim 52, the method comprising linking the HIV gp120, or a part thereof, with the said antigen.

58. (New) A vaccine comprising the compound according to Claim 52 and an adjuvant.

59. (New) A pharmaceutical composition comprising a compound according to Claim 52 and a pharmaceutically acceptable carrier.

60. (New-withdrawn) A method of immunizing an animal against a disease, the method comprising the step of administering to the animal a compound according to Claim 52.

61. (New-withdrawn) A method of combating a disease in an animal, the method comprising the step of administering to the animal a compound according to Claim 52.

62. (New-withdrawn) The method according to any one of Claims 60 or 61 wherein the disease is one caused by a pathogen selected from the group consisting of viruses, fungi, protozoa and helminths.

63. (New-withdrawn) The method according to Claim 62 wherein the pathogen is one associated with a disease selected from foot and mouth disease, swine vesicular disease, peste des petits ruminants, lumpy skin disease, bluetongue, African horse sickness, classical swine fever, Newcastle disease, vesicular stomatitis, rinderpest, Rift Valley fever, sheep pox and goat pox, African swine fever and highly pathogenic avian influenza.

64. (New-withdrawn) The method according to any one of Claims 60 or 61 wherein the animal is a mammal.

65. (New-withdrawn) The method according to Claim 64 wherein the animal is a companion animal or farm animal.

66. (New-withdrawn) The method according to Claim 65 wherein the animal is a cow, sheep, horse, pig, goat, dog, cat or rabbit.

67. (New-withdrawn) A method of determining whether an animal has been administered the compound of Claim 52, the method comprising determining whether the animal has or had an immune response to HIV gp120.

68. (New-withdrawn) The method of Claim 67 further comprising determining whether the animal has or had an immune response to the antigen.

69. (New) An immunogenic composition comprising a polypeptide having an HIV-1 gp120 amino acid sequence, or a part thereof, fused at the N- or C-terminal to all or part of a disease-associated polypeptide of an animal, wherein the HIV-1 gp120 amino acid sequence, or a part thereof, is able to bind the polypeptide to a DC-SIGN protein expressed at the surface of a dendritic cell of the animal, wherein all or part of the disease-associated polypeptide is an antigen capable of eliciting an immune response to a disease of the animal.

70. (New) The immunogenic composition of claim 60, wherein the HIV-1 gp120 amino acid sequence, or a part thereof, is further able to give rise to an antibody response in the animal.

71. (New) The immunogenic composition of claim 60, wherein the disease of the animal is a disease caused by a pathogen, wherein the disease-associated polypeptide is a polypeptide of the pathogen.

72. (New) The immunogenic composition of claim 60, wherein the animal is a farm animal or a companion animal.